Comparison of value of biomarkers in diagnosing lung cancer: An overview of systematic reviews protocol

摘要

Background: In both sexes combined, lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Furthermore, the incidence rate is increasing in many countries. Many lung cancer patients have a poor prognosis because they are usually diagnosed at an advanced stage. Therefore, there is an urgent need to develop effective methods for early diagnosis of lung cancer . Some systematic reviews have evaluated the value of biomarkers for diagnosing lung cancer . However, it remains unclear which biomarker has superior performance for early and accurate detection of lung cancer . This overview aims to assess the methodological and reporting quality of available systematic reviews and to find an optimal biomarker for diagnosing lung cancer . Methods: We searched PubMed, Embase.com, the Cochrane Library of Systematic Reviews, and Web of Science to identify relevant systematic reviews including randomized controlled trials, cross-sectional studies, case-control studies, or cohort studies that reported the value of biomarkers for diagnosing lung cancer . The methodological quality will be assessed using AMASAR-2 checklist, and the reporting quality will be assessed using PRISMA-DTA checklist. Bubble plot will be generated to map the biomarkers, methodological and reporting quality. The pairwise meta-analysis and indirect comparisons will be performed using STATA 13.0. Results: The results of this study will be published in a peer-reviewed journal Conclusion: This overview will provide comprehensive evidence of different biomarkers for the diagnosis of lung cancer . Ethics and dissemination: Ethics approval and patient consent are not required as this study is an overview based on published systematic reviews.